AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip® LAA Exclusion System, the most widely placed left atrial appendage device worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.
Mason, US
430 (est)

Key People at AtriCure

Michael H. Carrel

Michael H. Carrel

President & CEO
Thomas Hancock

Thomas Hancock

M. Andrew Wade

M. Andrew Wade

Lee Wrubel

Lee Wrubel

Mike Hooven

Mike Hooven

Founder &Director

AtriCure Locations

Mason, US
Minnetonka, US
San Ramon, US
Amsterdam, NL
Minneapolis, US
Cincinnati, US
Morrisville, US
West Chester, US

AtriCure Metrics

AtriCure Summary

Market capitalization

$547 M

Closing share price


AtriCure Market Value History

AtriCure Online Presence

AtriCure Company Life